< 生产厂家价格 >

氟替卡松丙酸酯

氟替卡松丙酸酯用途

Fluticasone丙酸盐是糖皮质激素受体(GR)激动剂。

点击显示

氟替卡松丙酸酯名称

[ CAS 号 ]:
80474-14-2

[ 中文名 ]:
氟替卡松丙酸酯

[ 英文名 ]:
Fluticasone propionate

[中文别名 ]:

丙酸氟替卡松

[英文别名 ]:

Fluticasone propionate (JAN/USAN)
Flonase
FLUNASE
Flovent DPI
Flutide N
Flixonase
Flixotide
flutide
MFCD08064194
Fluticasone propionate

氟替卡松丙酸酯生物活性

[ 描述 ]:

Fluticasone丙酸盐是糖皮质激素受体(GR)激动剂。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体

研究领域 >> 炎症/免疫

[参考文献]

[1]. McKeage K. Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. Drugs. 2013 Feb;73(2):195-206.

[相关活性小分子]

氟替卡松丙酸酯物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
568.3±50.0 °C at 760 mmHg

[ 熔点 ]:
275 °C

[ 分子式 ]:
C₂₅H₃₁F₃O₅S

[ 分子量 ]:
500.571

[ 闪点 ]:
297.5±30.1 °C

[ 精确质量 ]:
500.184418

[ PSA ]:
105.97000

[ LogP ]:
3.73

[ 外观性状 ]:
结晶固体

[ 蒸汽压 ]:
0.0±3.5 mmHg at 25°C

[ 折射率 ]:
1.556

[ 储存条件 ]:
Store at RT

[ 水溶解性 ]:
DMSO: ≥10 mg/mL

氟替卡松丙酸酯MSDS

氟替卡松丙酸酯毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: BV7980000

CHEMICAL NAME :: Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1- oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)-

CAS REGISTRY NUMBER :: 80474-14-2

LAST UPDATED :: 199312

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C25-H31-F3-O5-S

MOLECULAR WEIGHT :: 500.62

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1493,1992

TYPE OF TEST :: LC - Lethal concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >40770 ug/m3/1H

TOXIC EFFECTS :: Cardiac - changes in heart weight

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1501,1992

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >1 gm/kg

TOXIC EFFECTS :: Endocrine - other changes Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1493,1992 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2100 ug/m3/1H/78W-I

TOXIC EFFECTS :: Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight Blood - changes in leukocyte (WBC) count

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1509,1992

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 6139 ug/kg/1Y-I

TOXIC EFFECTS :: Endocrine - changes in adrenal weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in erythrocyte (RBC) count

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1543,1992 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1100 ug/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1597,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1100 ug/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - postpartum Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1597,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 105 ug/kg

SEX/DURATION :: female 1-7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1573,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 52 ug/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - hepatobiliary system

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20,1643,1992

点击显示

氟替卡松丙酸酯安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 安全声明 (欧洲) ]:
S22-S24/25

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
BV7980000

[ 海关编码 ]:
2937229000

氟替卡松丙酸酯合成路线

氟替卡松丙酸酯上下游产品

氟替卡松丙酸酯上游产品

氟替卡松丙酸酯下游产品

氟替卡松丙酸酯制备

化合物(Ⅰ)先和N，N-二甲基硫代氯甲酰胺反应后，再水解得到相应的硫代羧酸(Ⅱ)，然后和-溴-氟甲烷反应酯化，得丙酸氟替卡松。

点击显示

氟替卡松丙酸酯海关

[ 海关编码 ]: 2937229000

氟替卡松丙酸酯文献

Environmental friendly method for urban wastewater monitoring of micropollutants defined in the Directive 2013/39/EU and Decision 2015/495/EU.

J. Chromatogr. A. 1418 , 140-9, (2015)

The fate and removal of organic micropollutants in the environment is a demanding issue evidenced by the recent European policy. This work presents an analytical method for the trace quantification of...

A transgenic zebrafish model for monitoring glucocorticoid receptor activity.

Genes. Brain. Behav. 0 , (2014)

Gene regulation resulting from glucocorticoid receptor and glucocorticoid response element interactions is a hallmark feature of stress response signaling. Imbalanced glucocorticoid production and glu...

The use of hydrazine-based derivatization reagents for improved sensitivity and detection of carbonyl containing compounds using MALDI-MSI.

Anal. Bioanal. Chem 407(8) , 2085-94, (2015)

Hydrazine-based derivatization reagents have been used to detect the presence of the carbonyl containing glucocorticoid fluticasone proprionate in rat lung tissue by MALDI-MSI. Such reagents also act ...

更多文献

氟替卡松丙酸酯

氟替卡松丙酸酯用途

氟替卡松丙酸酯名称

氟替卡松丙酸酯生物活性

氟替卡松丙酸酯物理化学性质

氟替卡松丙酸酯MSDS

详细MSDS(安全技术说明书)

氟替卡松丙酸酯毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

氟替卡松丙酸酯安全信息

氟替卡松丙酸酯合成路线

详细合成路线

氟替卡松丙酸酯上下游产品

氟替卡松丙酸酯上游产品

氟替卡松丙酸酯下游产品

氟替卡松丙酸酯制备

氟替卡松丙酸酯海关

氟替卡松丙酸酯文献

相关药品：

推荐生产厂家/供应商：

相关化合物